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A study was designed to determine the interactions, both 
clinical and pharmacokinetic, between methadone and 
lopinavir-ritonavir. Results demonstrated a 36% reduction 
in the methadone area under the plasma concentration-
time curve after the introduction of lopinavir-ritonavir, 
with no coincident symptoms of opioid withdrawal and no 
requirement for methadone dose adjustment. 
Combination antiretroviral therapy is the standard 
treatment for HIV infection [1]. Previous studies have 
described the significant interaction between methadone 
and the nonnucleoside reverse-transcriptase inhibitors 
efavirenz and nevirapine, which results in symptoms of 
opioid withdrawal and, thus, requires methadone dose 
adjustment [2, 3]. Lopinavir (Lpv) is a protease inhibitor 
that is coformulated with ritonavir (Rtv) [4]. The 
coforinulation results in pharmacokinetic enhancement 
by Rtv and subsequent increased Lpv exposure. In vitro 
and in vivo studies have demonstrated that Lpv-Rtv is a 
potent inhibitor of the cytochrome enzymes P-450 3A4 
(CYP3A4) and 2D6 (CYP2D6), which are primarily Rtv 
mediated. Agents that are extensively metabolized by 
CYP3A4 and that have high first-pass metabolism 
appear to be most susceptible to large increases in the 
area under the plasma concentration-time curve (AUC) 
when they are coadministered with Lpv-Rtv. However, 
interactions can be complex, and Lpv-Rtv both induces 
its own metabolism and increases the biotransformation 
of some drugs 
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that are metabolized by CYP450 enzymes and by 
glucuroni-dation. Thus, in a study of healthy volunteers, 
there was a 47% reduction in the methadone AUC when 
methadone was co-administered with Lpv-Rtv [5]. 
 A recent unpublished review of all injection drug 
users (IDUs) who were receiving Lpv-Rtv at the Genito 
Urinary Medicine and Infectious Diseases (GUIDE) 
Clinic in St. James’s Hospital (Dublin, Ireland) 
demonstrated that none of the 14 patients who were 
evaluated complained of having any symptoms of 
methadone withdrawal (S.C., L McCullough, C.B., and 
P.M., unpublished data). This unexpected result 
prompted us to design a pharmacokinetic study to 
determine the pharmacokinetic interaction between 
Lpv-Rtv and methadone. 
 Patients and methods. Patients who fulfilled 
standard criteria to begin receiving antiretroviral therapy 
and who were also receiving methadone maintenance 
therapy on a regular basis were recruited to participate 
in the study. The study was approved by the local ethics 
committee {the joint research and ethics committee of 
Adelaide and Meath Hospital, incorporating the 
National Children’s Hospital, in Dublin). 
 The pharmacokinetics of methadone were 
determined when the medication was administered 
alone (on day 1 of the study) and in combination with 
the presence of antiretroviral therapy (on day 1 of the 
study). After 3 days of receiving standardized directly 
observed methadone therapy in their drug treatment 
clinic, the patients were seen in the day ward at 8:30 
A.M. on study day 1, at which time an intravenous 
cannula was inserted to facilitate blood sampling. The 
patients were then administered their daily methadone 
dose under supervision, and blood samples were 
obtained for methadone analysis at 0, 1, 2, 3, 4, 5, 6, 7, 
8, and 24 h after dosing. 
 The blood samples underwent centrifugation 
without delay, and the separated plasma was heated to 
58°C for 30 min to inactivate HIV. Plasma was stored at 
-70°C until drug analysis could be performed by HPLC. 
Patients then commenced receiving antiretroviral 
therapy that included 2 nucleoside reverse-transcriptase 
inhibitors plus Lpv-Rtv (Kaletra; Abbott 
Pharmaceutical). On the morning of day 14 of the study, 
the patients returned to the day ward, and a 
pharmacokinetic profile was repeated. The procedure 
was identical to that followed on day 1, except for the 
addition of antiretroviral therapy (including Lpv-Rtv) to 
the medication administered in the morning. Any 
adjustment in methadone dose did not occur until after 
the second day of the pharmacokinetic study. 
 At each clinic visit, urine samples for toxicology 
screening were obtained under supervision, and patients 
were assessed 
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for evidence of methadone withdrawal (i.e., 
perspiration, agitation, sneezing, diarrhea, leg cramps, 
pupillary diameter, rhinorrhea, and yawning). None of 
the patients was prescribed any additional drugs that 
would be expected to interfere with the metabolism-of 
methadone. 
 Plasma concentrations of methadone were 
determined as described elsewhere [2, 3]. The limit of 
quantification was 2 ng/mL. Interassay variability was 
determined with 3 different control samples that 
contained nominal methadone concentrations of 50, 
200, and 400 ng/mL and that had coefficients of 
variation that were 9.9%, 4.8%, and 4.2%, respectively. 
Intra-assay precision was determined with samples that 
contained 50 and 400 ng/mL. 
 The pharmacokinetic parameters that were 
determined for methadone included the maximum 
plasma concentration (Cmax) and the AUC to 24 h 
(AUC0-24h). Cmax was determined by inspection of the 
data. AUC values were determined by 
noncompartmental analysis done with the use of 
TOPFIT computer software (Gustav Fischer Verlag). 
Differences in pharmacokinetic parameters were 
compared by paired Student’s f test. P< .05 was 
considered statistically significant. 
 Results. Eight patients (4 men and 4 women) 
were enrolled in the study. The mean patient age was 34 
years (range, 23-38 years). All patients were found to be 
positive for hepatitis C antibody and PCR positive for 
hepatitis C virus, and all had normal biochemical 
hepatic function. Of the 8 patients, 2 (25%) had not 
previously received antiretroviral therapy, and 6 (75%) 
had previously received antiretroviral therapy. The 
mean baseline CD4 cell count was 148 X 106 cells/L 
(range, 65-282 X 106 cells/ L), and the mean HIV RNA 
level was 115,492 copies/mL (5-06 log; range, 8000 
copies/mL [3.09 log] to 250,000 copies/mL [5.4 log]). 
All patients received combination therapy that consisted 
of 3 antiretrovirals: stavudine, didanosine, and Lpv-Rtv 
(for 4 patients) or zidovudine, lamivudine, and Lpv-Rtv 
(for 4 patients). Antiretroviral drugs were chosen on the 
basis of previous patient exposure to antiretrovirals and 
the resistance profiles of the drugs, when available. The 
mean pretreatment methadone dose was 74 mg (range, 
40-100 mg; median, 80 mg). 
 All a patients who were recruited completed the 
study. The mean methadone AUC0-24h data for the 8 
patients, both before and after Lpv-Rtv therapy, are 
illustrated in figure 1. The mean AUC0-24h for 
methadone was significantly reduced from 10,835 
ng/h/mL (range, 3829-12,638 ng/h/mL) to 6943 
ng/h/mL (range, 3949-13,692 ng/h/mL) when Lpv-Rtv 
was coadministered (95% CI, 436-7892; P = .01). There 
was also a 44% reduction in the mean Cmax for 
methadone when Lpv-Rtv was coadministered. None of 
the patients experienced symptoms of methadone 
withdrawal during the study period or during the 
extended 6-week follow-up. 
 Discussion. A small study has reported 
conflicting findings of enhancement of both methadone 
effects and withdrawal 
 
symptoms when the drug is received in combination 
with Rtv, indinavir, and saquinavir (Sqv) [6]. 
Coformulation of Lpv with Rtv results in 
pharmacokinetic enhancement by Rtv and a subsequent 
increase in Lpv exposure [4]. In vitro and in vivo 
studies have demonstrated that Lpv-Rtv is a potent 
inhibitor of CYP3A4 and CYP2D6, which are primarily 
Rtv mediated [5]. In contrast, in a study of healthy 
volunteers, there was a 47% reduction in the methadone 
AUC when methadone was coadministered with Lpv-
Rtv [5]. It has therefore been suggested that patients 
who receive methadone and Lpv-Rtv concurrently may 
require an increased methadone dose as a result of in 
vivo induction of CYP450 enzymes and 
glucuronyltransferase [5]. 
 The results of our clinical experience with 
GUIDE Clinic patients who received both Lpv-Rtv and 
methadone are not consistent with a pharmacokinetic 
interaction that affects individual methadone dose 
requirements. Since Lpv-Rtv became available on an 
expanded-access program, data have been pro-
spectively collected on all IDUs who have received this 
drug as part of combination therapy. Lpv-Rtv was 
prescribed to 14 IDUs who concurrently received 
methadone. After receiving, therapy for 8 weeks, none 
of the patients experienced symptoms, consistent with 
methadone withdrawal. Maximum induction of hepatic 
enzymes occurs within 7-10 days of commencing; 
therapy with an enzyme inducer, so it is therefore 
unlikely that 
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any of these patients will experience methadone 
withdrawal at a later stage [7]. A retrospective study of 
patients who received Lpv-Rtv suggested that, contrary 
to the implications from the heal thy volunteer data, 
there is no need to adjust the methadone dose for 
patients who receive Lpv-Rrv (S.C., L. McCuIlough, 
C.B., and EM., unpublished data). 
 Our prospective pharmacokinetic study, which 
was performed to more accurately define the interaction 
between Lpv-Rtv and methadone, provided surprising 
results. Consistent with the data for healthy volunteers, 
there was a significant reduction (36%) in the 
methadone AUC0-24h when our patients received 
methadone in combination with Lpv-Rtv. However, 
despite this reduction, none of the patients either 
presented with symptoms or signs of methadone 
withdrawal or required a methadone dose adjustment. 
Three of the patients actually suggested that they 
believed that their methadone therapy lasted longer after 
antiretroviral therapy was initiated. The present study 
therefore confirmed the previous clinical observation 
that there is no need for dose adjustments for patients 
who receive methadone and Lpv. 
 The mechanism .for the reduction in the 
methadone AUC is unclear but will be related to one or 
more of the following: induction of CYP450 isozymes 
and/or glucuronyltransferase in’ the liver or 
gastrointestinal mucosa; induction of P-glycoprotein; 
altered plasma protein binding; and unequal effects of 
the drug on isomeric forms of methadone. Why a 
significant tie-’ crease in the methadone AUC should 
not lead to opioid withdrawal symptoms is also unclear. 
In a study of the clinical and pharmacological effects of 
Rtv and Sqv on methadone metabolism, Gerber et al. 
[81 provided important new data on the impact of 
altered plasma protein binding on methadone phar-
macokinetics. They demonstrated a significant 
discordant effect on R-isomers and S-isomers, with a 
40% reduction in S-methadone levels, compared with a 
32% reduction in R-methadone levels. Unlike other 
studies of methadone metabolism, the study by Gerber 
et al. [8| also corrected for changes in plasma protein 
binding associated with Rtv-Sqv therapy, and, of 
interest, it also demonstrated that the actual reduction in 
free methadone iso-mers was 24.6% for S-methadone 
and 19.6% for R-methadone. The implied hypothesis is 
that this less significant effect on free R-methadone 
levels is the reason why none of the 12 patients in their 
cohort experienced symptoms of opioid withdrawal 
during the study period. It is important to note, however, 
that 5 of their patients tested positive for either 
benzodiazepines or cocaine during the study, a finding 
that may have altered the severity of any withdrawal 
symptoms. 
 
 The study by Gerber et al. [8] further highlights 
the need for a consistent evaluation of opioid effects 
that uses both objective and subjective findings. 
Currently available questionnaires and examination 
techniques demonstrate the extremes of opioid 
withdrawal or overdose, and minor symptoms of 
withdrawal or overdose may be overlooked. Similarly, 
the possibility that patients involved in methadone 
pharmacokinetic studies are supplementing their 
methadone therapy with additional methadone or with 
other illicit drugs when they are not in the confines of 
the study institution must also be considered. 
 These data on the interaction between Lpv-Rtv 
and methadone demonstrate a significant reduction in 
the methadone AUC and Cmax, but the absence of overt 
opioid withdrawal symptoms in these patients will have 
a positive impact on the clinical usefulness of this drug 
for IDUs. Future studies of methadone interactions 
should include measures of isomeric and plasma 
protein-bound methadone and a standardized 
measurement of opioid effects. 
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